• Cholesterol and low-density lipoprotein (LDL)-cholesterol are causal factors for atheromatous cardiovascular disease (CVD), and moderate and higher levels are a near obligate for disease development.
• Statin drugs have overwhelming evidence of benefit at low side effect risk.
• Estimation of an individual's CVD risk is required from a number of factors, and CVD prevention requires attention to all abnormal modifiable factors in individuals at higher risk.
• Identifying, counselling, and appropriate treatment of individuals at high CVD risk is a current challenge for health care professionals.
• Guidelines have been produced to help, and Government has provided levers to encourage their application.
In the last 10 years the understanding of hyperlipidaemia has advanced greatly. This resource provides a practical approach to therapy, addresses common clinical problems and looks to the future of treatment for the condition, focusing on new therapeutic targets. In essence it translates clinical trial science into everyday clinical practice.
Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work.
